	销售和管理费用		日
Acadia Pharmaceuticals	USD 146.73M	21.82M	2025-12
Adma Biologics	USD 20.19M	2.86M	2025-12
ALKERMES	USD 187.2M	15.43M	2025-12
Alterity Therapeutics Limited	AUD 1.45M	703.96K	2025-12
AstraZeneca	USD 4.61B	4.46B	2025-12
BioCryst Pharmaceuticals	USD 95.78M	12.77M	2025-12
Bristol-Myers Squibb	USD 2.18B	392M	2025-12
Cipla	INR 13.25B	101.8M	2025-12
Clal Biotechnology	ILS 3.31M	513K	2022-12
Compugen	USD 2.21M	120K	2025-12
CSL	USD 1.23B	498M	2025-12
Eli Lilly	USD 3.13B	391.3M	2025-12
Esperion Therapeutics	USD 39.42M	456K	2025-12
GlaxoSmithKline	GBP 2.68B	518M	2025-12
Grifols	EUR 320.45M	12.65M	2025-12
Halozyme Therapeutics	USD 64.64M	27.11M	2025-12
Ionis Pharmaceuticals	USD 130M	43.43M	2025-12
J&J	USD 6.75B	831M	2025-12
Merck	USD 2.85B	215M	2025-12
Minerva Neurosciences	USD 2.48M	58.79K	2024-09
Neurocrine Biosciences	USD 301.8M	10.2M	2025-12
Novartis	USD 3.44B	128M	2025-12
Novavax	USD 25.53M	1.34M	2025-12
Pfizer	USD 4.08B	894M	2025-12
Roche Holding	CHF 7.28B	3.99B	2025-12
Sanofi	EUR 2.75B	455M	2025-12
Takeda	JPY 282.78B	29.23B	2025-12
Vanda Pharmaceuticals	USD 39.28M	1.71M	2024-12